Your browser doesn't support javascript.
loading
Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma.
Hellerstedt, Beth A; Vogelzang, Nicholas J; Kluger, Harriet M; Yasenchak, Christopher A; Aftab, Dana T; Ramies, David A; Gordon, Michael S; Lara, Primo.
Afiliação
  • Hellerstedt BA; US Oncology Research, LLC, McKesson Specialty Health, The Woodlands, TX; Texas Oncology, Central Austin Cancer Center, Austin, TX. Electronic address: beth.hellerstedt@usoncology.com.
  • Vogelzang NJ; US Oncology Research/Comprehensive Cancer Centers NV, Las Vegas, NV.
  • Kluger HM; Yale Cancer Center, New Haven, CT.
  • Yasenchak CA; US Oncology Research/Willamette Valley Cancer Institute, Eugene, OR.
  • Aftab DT; Exelixis, South San Francisco, CA.
  • Ramies DA; Exelixis, South San Francisco, CA.
  • Gordon MS; HonorHealth Research Institute, Scottsdale, AZ.
  • Lara P; University of California, Davis, CA.
Clin Lung Cancer ; 20(2): 74-81.e1, 2019 03.
Article em En | MEDLINE | ID: mdl-30528315
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piridinas / Carcinoma Pulmonar de Células não Pequenas / Anilidas / Neoplasias Pulmonares / Antineoplásicos Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piridinas / Carcinoma Pulmonar de Células não Pequenas / Anilidas / Neoplasias Pulmonares / Antineoplásicos Idioma: En Ano de publicação: 2019 Tipo de documento: Article